Signaling Signatures and Functional Properties of Anti-Human CD28 Superagonistic Antibodies
Open accessThe DOI matches its Crossref record; 45 of the 46 references it cites were found in a registry or an index; 10 of the 61 sources its claims cite were checked for support.
Abstract
Superagonistic CD28 antibodies (CD28SAs) activate T lymphocytes without concomitant perturbation of the TCR/CD3-complex. In rodents these reagents induce the preferential expansion of regulatory T cells and can be used for the treatment of autoimmune diseases. Unexpectedly, the humanized CD28 superagonist TGN1412 caused severe and life threatening adverse effects during a recently conducted phase I clinical trail. The underlying molecular mechanisms are as yet unclear. We show that TGN1412 as well as the commercially available CD28 superagonist ANC28.1 induce a delayed but extremely sustained calcium response in human naïve and memory CD4+ T cells but not in cynomolgus T lymphocytes. The sustained Ca++-signal was associated with the activation of multiple intracellular signaling pathways and together these events culminated in the rapid de novo synthesis of high amounts of pro-inflammatory cytokines, most notably IFN-gamma and TNF-alpha. Importantly, sustained transmembranous calcium flux, activation of Src-kinases as well as activation of PI3K were found to be absolutely required for CD28SA-mediated production of IFN-gamma and IL-2. Collectively, our data suggest a molecular basis for the severe side effects caused by TGN1412 and impinge upon the relevance of non-human primates as preclinical models for reagents that are supposed to modify the function of human T cells.
Overview
CoChat Summary
TL;DR
Two anti-human CD28 superagonists, TGN1412 and ANC28.1, induce a delayed but extremely sustained calcium signal in human CD4+ T cells that drives multiple signaling pathways and rapid pro-inflammatory cytokine production. This response is not reproduced in cynomolgus or rhesus monkey T cells despite conserved CD28 extracellular domains, suggesting a molecular basis for TGN1412’s severe clinical side effects and questioning non-human primates as preclinical models.
Key findings
- ANC28.1 and TGN1412 induced a sustained Ca++ signal in human naïve and memory CD4+ T cells that lasted for more than six hours without significant decrease; conventional CD28 mAbs did not induce detectable Ca++ flux.
- CD28SA stimulation activated multiple pathways (Erk1/2, JNK, p38, AKT, GSK3β-1, NF-ATc1, IκBα) and led to rapid de novo cytokine synthesis; IFN-γ was detectable in culture supernatant already 90–120 minutes after stimulation.
- IFN-γ and IL-2 production required transmembranous calcium flux, Src-kinase activity, PI3K activity, and calcineurin/NF-AT signaling; EGTA, cycloheximide, PP2, cyclosporin A, Wortmannin, and LY294002 each abrogated these responses.
- Despite complete conservation of CD28 extracellular and cytoplasmic domains between human, rhesus, and cynomolgus monkeys, TGN1412 induced only a very low calcium signal in monkey T cells; sequencing of 14 rhesus and 11 cynomolgus monkeys found three non-conservative amino acid exchanges in the transmembrane region and one in the leader sequence.
Methods
- Human T cells were purified from healthy volunteers; monkey T cells were purified from Macaca mulatta and Macaca fascicularis blood.
- Proliferation was measured by [3H]-thymidine incorporation; signaling was assessed by phosphospecific western blotting; calcium responses were measured by Indo-1 flow cytometry and Fura2 live video microscopy; cytokines were measured by cytometric bead arrays and ELISA.
- CD28 cDNAs from 14 rhesus and 11 cynomolgus monkeys were sequenced and compared with human CD28; TGN1412 binding and T cell subsets were analyzed by FACS.
Limitations
- The paper states that it is unclear how transmembrane calcium flux is induced and maintained upon CD28SA stimulation, which kinase phosphorylates LAT, and whether PI3K regulates IL-2/IFN-γ via AKT; it also cannot exclude differences in CD28 microcluster assembly or dynamics.
- The paper notes that CD28SAs do not fully activate human T cells, as β1/β2-integrin activation, F-actin formation, and cell migration were not observed.
- Evident from the text: the mechanistic work is primarily in vitro with human and monkey T cells, and the proposed link to TGN1412’s clinical cytokine storm is inferential rather than directly demonstrated in vivo.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Sustained calcium flux, T cell proliferation, and T cell signaling upon TGN1412 treatment. (A) Freshly isolated human T cells were treated as described in Fig. 2 using the superagonistic CD28 specific mAb TGN1412 (10 µg/ml; red triangle). For crosslinking, 20 µg/ml of monoclonal mouse anti-human IgG4 was used (black triangle) and induction of the Ca++-response was monitored. (B) 5×104 freshly prepared human T-cells/96-well were stimulated with the indicated concentrations of ANC28.1 or TGN1412 or were left untreated as a control. For crosslinking of ANC28.1, a polyclonal goat anti-mouse antiserum was used and crosslinking of TGN1412 was performed as described in (A). Concentrations for crosslinking were the following: 0.1–1.25 µg/ml primary Ab+2.5 µg/ml crosslinker; 2.5 µg/ml primary Ab+5 µg/ml crosslinker; 5 µg/ml primary Ab+10 µg/ml crosslinker; 10 µg/ml primary Ab+20 µg/ml crosslinker. 72 hours after stimulation, cultures were pulsed with 3H-thymidine for 6 hours, then harvested and proliferation analyzed by counts per minute [cpm]. (C) 1×106 freshly prepared human T cells/lane were left untreated or were stimulated with 10 µg/ml ANC28.1 (first and third panel) followed by crosslinking with 20 µg/ml polyclonal goat anti-mouse antiserum or with 10 µg/ml TGN1412 (right panel) followed by crosslinking as described in (A) for the indicated periods of time. As a control, cells were activated with a 1∶50 dilution of ascites fluid of CD3 mAb MEM92 (second panel). Postnuclear lysates were processed for western blotting using the indicated phosphospecific antibodies. Western blotting using an anti-actin antibody was performed as loading control.](https://figures.cochat.ai/paper-figures/9abb1f35781940be83230bd1813f743d/signaling-signatures-and-functional-properties-of-anti-human-cd28-superagonistic-figure-3.jpg)
![Figure 4 Cytokine production upon conventional and superagonistic CD28 stimulation of human T cells. 5×104 freshly prepared human T-cells/96-well were stimulated with the indicated combination of antibodies as described in Fig. 1A or were left untreated as controls. At 48 hours 50 µl culture supernatant was removed from each well. Supernatants obtained from 3 wells were pooled and cytokine content was determined using the Cytokine Bead Array from BD in signals per minute [spm] (black bars). Additionally, induction of T cell proliferation was monitored upon treatment with the indicated antibody combinations (gray bars). 72 hours after stimulation, cultures were pulsed with 3H-thymidine for 6 hours, then harvested and proliferation analyzed by counts per minute [cpm]. Data represent the mean of 5 individual experiments.](https://figures.cochat.ai/paper-figures/0d5cb189a0f2466ba5320666f039e770/signaling-signatures-and-functional-properties-of-anti-human-cd28-superagonistic-figure-4.jpg)


Verification
Claims the paper makes
8 Valid · 3 Not valid · 33 Not checked · 105 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“However, in line with a recent report [33] we did not see obvious differences in CD28 cluster formation upon CD28SA vs. CD28 stimulation by confocal laserscanning microscopy (data not shown).”
§ Signaling Signatures and Functional Properties of Anti-Human CD28 Superagonistic Antibodies > Discussion
What the sources say
- Disputedcites [33] Sester U Wabnitz GH Kirchgessner H Samstag Y 2007 Ras/PI3Kinase/cofilin-independent activation of human CD45RA(+) and CD45RO(+) T cells by superagonistic CD28 stimulation. Eur J Immunol 37 2881 2891 17899554 sourceExperimental — accuracy not yet measured
The section “Incomplete receptor clustering after 5.11A1 stimulation” (page unavailable) reports an obvious difference: conventional CD3/CD28 stimulation produced large, polarized receptor clusters, whereas superagonistic CD28 stimulation produced only small clusters that did not coalesce at one pole. The “Capping” methods section confirms that the images were obtained by confocal laser-scanning microscopy. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Every source the paper cites for this claim was checked and supports it.
In the paper
“Note that a conventional CD28 antibody only induced the known activation of the AKT and the JNK pathways (data not shown and [31]).”
§ Signaling Signatures and Functional Properties of Anti-Human CD28 Superagonistic Antibodies > Results > Intracellular signaling events induced by ANC28.1 and TGN1412
What the sources say
- Supportedcites [31] Saez-Rodriguez J 2007 A comprehensive logical model provides insights into T-cell signaling; submitted for publication. PMC1950951 17722974 source
The Results (Analysis of the Logical Model; page not supplied) report that a non-superagonistic CD28 antibody induced sustained JNK phosphorylation and that CD28 alone selectively activated JNK, not ERK. The Figure 4 caption in the Results also reports CD28-induced PKB (AKT) activation. Together, these support the cited comparison of AKT and JNK pathway activation. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“While conventional CD28 mAbs bind CD28 close to the binding site of the natural CD28 ligands, CD80 and CD86, CD28 superagonists bind to a laterally exposed loop within the extracellular domain of CD28 [8].”
§ Signaling Signatures and Functional Properties of Anti-Human CD28 Superagonistic Antibodies > Introduction
What the sources say
- Supportedcites [8] Luhder F Huang Y Dennehy KM Guntermann C Muller I 2003 Topological requirements and signaling properties of T cell-activating, anti-CD28 antibody superagonists. J Exp Med 197 955 966 12707299 PMC2193880 source
The Introduction states that conventional anti-CD28 mAbs bind at or close to the B7 binding site. The section on separation of epitopes likewise places the epitopes of two conventional mAbs close to that site. These passages support the attributed claim about proximity to the natural ligands’ binding site; page numbers were not supplied. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“(i) we show that (similar to rat T cells [12]) the Ca++-signal produced by ANC28.1 required expression of a functional TCR (Fig. 2B);”
§ Signaling Signatures and Functional Properties of Anti-Human CD28 Superagonistic Antibodies > Discussion
What the sources say
- Supportedcites [12] Dennehy KM Elias F Na SY Fischer KD Hunig T 2007 Mitogenic CD28 signals require the exchange factor Vav1 to enhance TCR signaling at the SLP-76-Vav-Itk signalosome. J Immunol 178 1363 1371 17237383 source
The Discussion (p. 7) states that a functional TCR is required for CD28-superagonist signaling. The Results (pp. 3–4) show that TCR-deficient cells did not respond to superagonist stimulation and identify Ca²⁺ flux as part of that signaling pathway. (LLM, conf=0.86)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In agreement with data obtained in rat T cells [12], ANC28.1 stimulation did not result in a detectable tyrosine phosphorylation of the protein tyrosine kinase ZAP70 (Fig. 1B, middle panel) although ZAP70 is believed to be primarily responsible for LAT phosphorylation upon TCR-stimulation.”
§ Signaling Signatures and Functional Properties of Anti-Human CD28 Superagonistic Antibodies > Discussion
What the sources say
- Partly supportedcites [12] Dennehy KM Elias F Na SY Fischer KD Hunig T 2007 Mitogenic CD28 signals require the exchange factor Vav1 to enhance TCR signaling at the SLP-76-Vav-Itk signalosome. J Immunol 178 1363 1371 17237383 sourceExperimental — accuracy not yet measured
The Results (p. 4) report that CD28-superagonist stimulation did not induce Zap-70 phosphorylation in human Jurkat T cells. The paper does not identify the antibody as ANC28.1 in the passages examined, so it supports the finding but not the claim about that specific antibody. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
86 more claims · 1 with their cited sources checked
Create a free account to see all 149 claims and every source verdict.
- It may state two separate claims as one. 22
- Not yet classified. 20
- Probably not a substantial claim. 22
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, it has been previously published that ANC28.1 induces greater or similar in vitro cytokine release than TGN1412 (Waibler et al., 2008), which is in contrast to our findings here that TGN1412 is far more potent than ANC28.1.”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Waibler et al., 2008
Citations
Cites
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164 · cited 3×
“These were associated with the induction of a cytokine storm, i.e. the release of high amounts of proinflammatory cytokines, most notably TNF-a and IFN-c [21].”
BackgroundInfluentialEvolutionary and biomedical insights from the rhesus macaque genome.
Gibbs, R. A., Rogers, J., Katze, M. G., Bumgarner, R., Weinstock, G. M., Mardis, E. R., Remington, K. A., Strausberg, R. L., Venter, J. C., Wilson, R. K., et al. (2007) · Science · doi:10.1126/science.1139247 · Cited by 1,403
Schwartz, R. H. (1992) · Cell · doi:10.1016/s0092-8674(05)80055-8 · Cited by 1,293 · cited 1×
“According to the currently accepted model of T cell activation, two signals are required to fully activate resting naive T lymphocytes. The primary signal is provided by the clonotypic T cell receptor (TCR) after recognition of antigen/MHC-complexes on the surface of antigen presenting cells. However, this signal by i…”
BackgroundZhang, W., Sloan-Lancaster, J., Kitchen, J., Trible, R. P., & Samelson, L. E. (1998) · Cell · doi:10.1016/s0092-8674(00)80901-0 · Cited by 1,267 · cited 1×
“The transmembrane adapter protein LAT (Linker for Activation of T cells) represents a 35 kDa polypeptide that is essential for T cell activation [23,24].”
BackgroundCalcium signalling in lymphocyte activation and disease
Feske, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2152 · Cited by 1,043 · cited 1×
“Moreover, it will be important to determine the functional roles of the recently identified ORAI1 and STIM proteins in CD28SA-induced transmembrane Caflux [40].”
BackgroundVarma, R., Campi, G., Yokosuka, T., Saito, T., & Dustin, M. L. (2006) · Immunity · doi:10.1016/j.immuni.2006.04.010 · Cited by 879
Calcium signaling mechanisms in T lymphocytes.
Lewis, R. S. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.497 · Cited by 860 · cited 1×
“S1 and [27]) induced a rapid, strong, and transient rise in intracellular Ca whereas the CD28SA-mediated Ca-signal started delayed and was of lower intensity (Fig.”
BackgroundCD28-mediated co-stimulation: a quantitative support for TCR signalling.
Acuto, O., & Michel, F. (2003) · Nature Reviews Immunology · doi:10.1038/nri1248 · Cited by 775 · cited 1×
“. In mouse and human T cells the dimeric transmembrane glycoprotein CD28 represents the most important co-stimulatory molecule. Under physiological conditions CD28-derived signals alone are not capable of inducing T cell activation, whereas simultaneous engagement of the TCR and CD28 (e.g. by its natural ligands CD80…”
BackgroundEssential Role of LAT in T Cell Development
Zhang, W., Sommers, C. L., Burshtyn, D. N., Stebbins, C. C., DeJarnette, J. B., Trible, R. P., Grinberg, A., Tsay, H. C., Jacobs, H. M., Kessler, C. M., et al. (1999) · Immunity · doi:10.1016/s1074-7613(00)80032-1 · Cited by 547 · cited 1×
“The transmembrane adapter protein LAT (Linker for Activation of T cells) represents a 35 kDa polypeptide that is essential for T cell activation [23,24].”
BackgroundUnifying concepts in CD28, ICOS and CTLA4 co-receptor signalling.
Rudd, C. E., & Schneider, H. (2003) · Nature Reviews Immunology · doi:10.1038/nri1131 · Cited by 392 · cited 1×
“(reviewed in [3,4]).”
Cited by
The safety and side effects of monoclonal antibodies
Hansel, T. T., Kropshofer, H., Singer, T., Mitchell, J. A., & George, A. J. T. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3003 · Cited by 1,144
CD28 Costimulation: From Mechanism to Therapy
Esensten, J. H., Helou, Y. A., Chopra, G., Weiss, A., & Bluestone, J. A. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.020 · Cited by 937
“, 2008), and the ability of this antibody to cause sustained calcium flux (Waibler et al., 2008), among many other hypotheses (Schraven and Kalinke, 2008).”
BackgroundDelivering safer immunotherapies for cancer
Milling, L., Zhang, Y., & Irvine, D. J. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.011 · Cited by 305
Eastwood, D., Findlay, L., Poole, S., Bird, C., Wadhwa, M., Moore, M., Burns, C., Thorpe, R., & Stebbings, R. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00922.x · Cited by 300
“…suggested that differences in human- and macaque TGN1412-driven responses are due to the expression of inhibitory Siglecs on non-human primate T-cells, which have been lost during human evolution, rendering them less responsive to in vitro stimulation (Nguyen et al., 2006; Waibler et al., 2008).”
BackgroundResultWu, L., Seung, E., Xu, L., Rao, E., Lord, D. M., Wei, R. R., Cortez-Retamozo, V., Ospina, B., Posternak, V., Ulinski, G., et al. (2019) · Nature Cancer · doi:10.1038/s43018-019-0004-z · Cited by 259
Jutz, S., Leitner, J., Schmetterer, K., Doel-Perez, I., Majdic, O., Grabmeier-Pfistershammer, K., Paster, W., Huppa, J. B., & Steinberger, P. (2016) · Journal of Immunological Methods · doi:10.1016/j.jim.2016.01.007 · Cited by 207
“Accessory signals generated in T cells during their interaction with cells that present their cognate antigen can potently modulate TCR-signals and thus enhance or attenuate the activity of NF-κ B, NFAT and AP-1.”
Pien, G. C., Basner-Tschakarjan, E., Hui, D. J., Mentlik, A. N., Finn, J. D., Hasbrouck, N. C., Zhou, S., Murphy, S. L., Maus, M. V., Mingozzi, F., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36891 · Cited by 192
“Subsequent investigation demonstrated that superagonist activation of CD28 leads to a sustained calcium influx in human T cells, but not cynomolgus or rhesus monkey T cells (45).”
BackgroundEngels, N., König, L. M., Heemann, C., Lutz, J., Tsubata, T., Griep, S., Schrader, V., & Wienands, J. (2009) · Nature Immunology · doi:10.1038/ni.1764 · Cited by 177
“33 ) has been attributed to the ability of this antibody to induce long-lasting Ca 2+ entry across the T cell membran”
BackgroundMonoclonal antibody-induced cytokine-release syndrome
Bugelski, P. J., Achuthanandam, R., Capocasale, R. J., Treacy, G., & Bouman-Thio, E. (2009) · Expert Review of Clinical Immunology · doi:10.1586/eci.09.31 · Cited by 161
Targeting co-stimulatory pathways: transplantation and autoimmunity
Ford, M. L., Adams, A. B., & Pearson, T. C. (2014) · Nature Reviews Nephrology · doi:10.1038/nrneph.2013.183 · Cited by 157
The Role of Fc Receptors on the Effectiveness of Therapeutic Monoclonal Antibodies
Gogesch, P., Dudek, S., van Zandbergen, G., Waibler, Z., & Anzaghe, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168947 · Cited by 172
“Amongst other immune activating processes, also crosslinking of the TGN1412 Fc part has been observed to be critically involved in inducing cytokine secretion in vitro [41,75].”
BackgroundSelf-citationLinka, R. M., Risse, S. L., Bienemann, K., Werner, M., Linka, Y., Krux, F., Synaeve, C., Deenen, R., Ginzel, S., Dvorský, R., et al. (2012) · Leukemia · doi:10.1038/leu.2011.371 · Cited by 148
Self-citationMechanisms of Opioid-Mediated Inhibition of Human T Cell Receptor Signaling
Börner, C., Warnick, B., Šmída, M., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802763 · Cited by 123
“Activated Zap70 in turn phosphorylates the transmembrane adapter protein linker for activation of T cells (LAT) on at least four tyrosine residues, leading to the assembly of the calcium-initiation complex (14).”
BackgroundSelf-citationMuller, P., & Brennan, F. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.273 · Cited by 104
Warncke, M., Calzascia, T., Coulot, M., Balke, N., Touil, R., Kolbinger, F., & Heusser, C. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200090 · Cited by 102
“domain of CD28, the loss of Siglec-5 expression during human evolution (11, 12), or a different expression pattern of CD28 on a specific T cell subset (13).”
BackgroundHorvath, C. J., & Milton, M. N. (2009) · Toxicologic Pathology · doi:10.1177/0192623309332986 · Cited by 87
Safety of biologics, lessons learnt from TGN1412
Stebbings, R., Poole, S., & Thorpe, R. (2009) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2009.10.002 · Cited by 70
Vessillier, S., Eastwood, D., Fox, B. J., Sathish, J. G., Sethu, S., Dougall, T., Thorpe, S. J., Thorpe, R., & Stebbings, R. (2015) · Journal of Immunological Methods · doi:10.1016/j.jim.2015.04.020 · Cited by 76
“Rituximab is not negative in all CRA (Walker et al., 2011), in particular IL-6 release and B-cell activation is prominent in vitro and in vivo but this cytokine was not included in our panel (Agarwal et al., 2004; Jones et al., 2014).”
BackgroundMethodInfluentialSkartsis, N., Peng, Y., Ferreira, L. M. R., Nguyen, V. Q., Ronin, É., Müller, Y. D., Vincenti, F. G., & Tang, Q. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.783282 · Cited by 76
Liu, D., Krummey, S. M., Badell, I. R., Wagener, M. E., Schneeweis, L. A., Stetsko, D. K., Suchard, S. J., Nadler, S. G., & Ford, M. L. (2014) · The Journal of Experimental Medicine · doi:10.1084/jem.20130902 · Cited by 67
“This study highlighted the complexities of developing CD28-specific blocking reagents (Waibler et al., 2008a,b).”
Porciello, N., & Tuosto, L. (2016) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2016.02.004 · Cited by 61
CD28 Superagonists: What Makes the Difference in Humans?
Schraven, B. L., & Kalinke, U. (2008) · Immunity · doi:10.1016/j.immuni.2008.04.003 · Cited by 63
Self-citationSoto, P. C., Stein, L. L., Hurtado-Ziola, N., Hedrick, S. M., & Varki, A. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903420 · Cited by 56
“These include protection from higher numbers of Tregs in rodent populations and differences in calcium flux and intracellular cell signaling between human and nonhuman primates (54, 59, 68).”
BackgroundResultSchabowsky, R.-H., Elpek, K. G., Madireddi, S., Sharma, R. K., Yolcu, E. S., Bandura‐Morgan, L., Miller, R. E., MacLeod, K. J., Mittler, R. S., & Shirwan, H. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.09.127 · Cited by 58
“The signaling ability of CD28 superagonist Abs depends on a functional TCR [44;46].”
BackgroundInfluentialA more selective costimulatory blockade of the CD28-B7 pathway
Poirier, N., Blancho, G., & Vanhove, B. (2010) · Transplant International · doi:10.1111/j.1432-2277.2010.01176.x · Cited by 54
“It was shown that TGN1412 induces calcium responses in human naive and memory CD4+ T lymphocytes but not in monkey T lymphocytes [87].”
BackgroundNF-κB family of transcription factors: Biochemical players of CD28 co-stimulation
Tuosto, L. (2010) · Immunology Letters · doi:10.1016/j.imlet.2010.09.005 · Cited by 55
“At the molecular level, the superagonistic antiCD28 Abs induce the tyrosine phosphorylation of Vav-1, SLP-76 and PLC 1, Ca2+ flux and NF-ATc, the activation of PKC /NF- B and IL-2 production [96,97].”
BackgroundWolf, B., Morgan, H., Krieg, J., Gani, Z., Milicov, A., Warncke, M., Brennan, F. R., Jones, S., Sims, J., & Kießling, A. (2012) · Cytokine · doi:10.1016/j.cyto.2012.08.018 · Cited by 50
“1 at a concentration of 5 lg/ml resulted in a much higher overall release of all cytokines when compared with TGN1412L at all tested concentrations (up to 100 lg/ml) in the whole blood assay, despite both mAbs acting as anti-CD28 superagonists [22].”
The rise and fall of the CD 28 superagonist TGN 1412 and its return as TAB 08: a personal account
Hünig, T. (2016) · The FEBS Journal · doi:10.1111/febs.13754 · Cited by 47
CD28-Specific Immunomodulating Antibodies: What Can Be Learned From Experimental Models?
Poirier, N., Blancho, G., & Vanhove, B. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04032.x · Cited by 52
“A study showed that TGN1412 induces calcium responses in human naive and memory CD4+ T lymphocytes but not in monkey T lymphocytes (27), which could be explained by a lack of CD28 expression by CD4 effector memory cells in macaques (28).”
BackgroundTranscriptional regulation of Foxp3 gene: Multiple signal pathways on the road
Shen, Z., Chen, L., Hao, F., & Wu, J. (2009) · Medicinal Research Reviews · doi:10.1002/med.20152 · Cited by 48
“Unknown at that time was the precise mechanism by which CD28 superagonistic monoclonal antibody activated Foxp3 transcription.(150) Administration of the CD28 superagonistic antibody JJ316 was an efficient means to treat autoimmune diseases in rats,(151) but the humanized antibody TGN1412 caused devastating side effec…”
BackgroundCamperio, C., Muscolini, M., Volpe, E., Mitri, D. D., Mechelli, R., Buscarinu, M. C., Ruggieri, S., Piccolella, E., Salvetti, M., Gasperini, C., et al. (2014) · Immunology Letters · doi:10.1016/j.imlet.2013.12.020 · Cited by 47
TGN1412 Induces Lymphopenia and Human Cytokine Release in a Humanized Mouse Model
Weißmüller, S., Kronhart, S., Kreuz, D., Schnierle, B. S., Kalinke, U., Kirberg, J., Hanschmann, K.-M. O., & Waibler, Z. (2016) · PLoS ONE · doi:10.1371/journal.pone.0149093 · Cited by 45
Self-citationBartholomaeus, P., Semmler, L. Y., Bukur, T., Boisguerin, V., Römer, P. S., Tabares, P., Chuvpilo, S., Tyrsin, D. Y., Matskevich, A., Hengel, H., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302461 · Cited by 40
“T cells enriched from freshly isolated PBMCs are not strongly activated upon treatment with soluble superagonistic anti-CD28 mAb TGN1412 (8, 16).”
BackgroundMethodInfluentialSelf-citationHanson, A., Elpek, K., Duong, E., Shallberg, L., Fan, M., Johnson, C., Wallace, M., Mabry, G. R., Sazinsky, S., Pepper, L., et al. (2020) · PLOS ONE · doi:10.1371/journal.pone.0239595 · Cited by 39
“1) [23], stimulated CD4 T cell proliferation either in the presence or absence of signal 1 even when added in soluble form.”
BackgroundSingle CD28 stimulation induces stable and polyclonal expansion of human regulatory T cells
He, X., Smeets, R. L., van Rijssen, E., Boots, A. M. H., Joosten, I., & Koenen, H. J. P. M. (2017) · Scientific Reports · doi:10.1038/srep43003 · Cited by 38
Aptamers for CD Antigens: From Cell Profiling to Activity Modulation
Nozari, A., & Berezovski, M. V. (2016) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2016.12.002 · Cited by 37
“For quite some time, anti-CD28 antibodies have been used as artificial co-stimulatory ligands, particularly in the activation of tumor-antigen-specific lymphocytes.(31,32) Some other humanized antibodies with co-stimulatory capacity, such as antibodies for CD40, OX40, and 4-1BB, are currently in clinical trials.”
BackgroundA non-conserved amino acid variant regulates differential signalling between human and mouse CD28
Porciello, N., Grazioli, P., Campese, A. F., Kunkl, M., Caristi, S., Mastrogiovanni, M., Muscolini, M., Spadaro, F., Favre, C., Nunès, J. A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03385-8 · Cited by 38
Targeting human CD27 with an agonist antibody stimulates T-cell activation and antitumor immunity
Thomas, L. J., He, L.-Z., Marsh, H. C., et al. (2014) · OncoImmunology · doi:10.4161/onci.27255 · Cited by 31
Reed, D. M., Paschalaki, K. E., Starke, R. D., Mohamed, N. A., Sharp, G., Fox, B. J., Eastwood, D., Bristow, A., Ball, C., Vessillier, S., et al. (2015) · The FASEB Journal · doi:10.1096/fj.14-268144 · Cited by 32
“ANC28 is a fully murine antibody that also acts as an anti-CD28 superagonist and thereby mimics the effects of TGN1412 in human tissue bioassays (22).”
BackgroundCassotta, M., Pistollato, F., & Battino, M. (2019) · ALTEX · doi:10.14573/altex.1910011 · Cited by 39
High content cellular immune profiling reveals differences between rhesus monkeys and men
Magalhaes, I., Vudattu, N. K., Ahmed, R. K. S., Kühlmann‐Berenzon, S., Ngo, Y., Sizemore, D. R., Wehlin, L., Weichold, F., Andersson, J., Skeiky, Y. A. W., et al. (2010) · Immunology · doi:10.1111/j.1365-2567.2010.03284.x · Cited by 30
Animal extrapolation in preclinical studies: An analysis of the tragic case of TGN1412
Lemoine, M. (2016) · Studies in History and Philosophy of Science Part C Studies in History and Philosophy of Biological and Biomedical Sciences · doi:10.1016/j.shpsc.2016.12.004 · Cited by 28
ICOS-LICOS interaction is critically involved in TGN1412-mediated T-cell activation
Weissmüller, S., Semmler, L. Y., Kalinke, U., Christians, S., Müller-Berghaus, J., & Waibler, Z. (2012) · Blood · doi:10.1182/blood-2011-12-401083 · Cited by 26
Self-citationWalker, M., Makropoulos, D., Achuthanandam, R., Arsdell, S. V., & Bugelski, P. J. (2011) · International Immunopharmacology · doi:10.1016/j.intimp.2011.06.001 · Cited by 27
“This leads to sustained calcium flux and activation of T cells [15].”
BackgroundPoirier, N., Mary, C., Bas‐Bernardet, S. L., Daguin, V., Belarif, L., Chevalier, M., Hervouet, J., Minault, D., Ville, S., Charpy, V., et al. (2014) · mAbs · doi:10.4161/mabs.28375 · Cited by 28
“Concerning TGN1412, whereas binding affinity for CD28 was similar between cynomolgus macaques and humans,(21,32,33) PBMC from macaques were not stimulated in vitro by immobilized TGN1412, contrary to results with human cells.(24,34) It was first suggested that the differences could be due to the loss of Siglecs inhibi…”
ResultDanilenko, D. M., & Wang, H. (2012) · Toxicologic Pathology · doi:10.1177/0192623311430237 · Cited by 24
“Although cultured cynomolgus PBMCs show binding and a limited response to immobilized TGN1412, these cells do not show the strong activation that human T cells demonstrated following TGN1412 binding, supporting the hypothesis that there are key differences in the response of human and nonhuman primate lymphocytes to T…”
BackgroundWere monocytes responsible for initiating the cytokine storm in the TGN1412 clinical trial tragedy?
Sandilands, G. P., Wilson, M. R., Huser, C. A. M., Jolly, L., Sands, W. A., & McSharry, C. P. (2010) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2010.04264.x · Cited by 24
Surrogate approaches in development of monoclonal antibodies
Bornstein, G. G., Klakamp, S. L., Andrews, L., Boyle, W. J., & Tabrizi, M. A. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.09.014 · Cited by 20
A Proteomic View at T Cell Costimulation
Lichtenfels, R., Rappl, G., Hombach, A. A., Recktenwald, C. V., Dressler, S. P., Abken, H., & Seliger, B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032994 · Cited by 20
“tion of harmful pro-inflammatory cytokine storms [21].”
T Cells of Infants Are Mature, but Hyporeactive Due to Limited Ca2+ Influx
Schmiedeberg, K., Krause, H., Röhl, F., Hartig, R., Jorch, G., & Brunner-Weinzierl, M. C. (2016) · PLoS ONE · doi:10.1371/journal.pone.0166633 · Cited by 22
Self-citation3D and 4D imaging of immune cells in vitro and in vivo
Nitschke, C., Garin, A., Kosco‐Vilbois, M. H., & Gunzer, M. (2008) · Histochemistry and Cell Biology · doi:10.1007/s00418-008-0520-x · Cited by 22
“The use of Xuorescent indicators of cell physiology, such as Calcium-sensitive dyes is also possible allowing the high-resolution imaging of cell signaling (Gunzer et al. 2000, 2004; Waibler et al. 2008).”
MethodSelf-citationMedina, M. Á., Couturier, J. P., Feske, M. L., Mahne, A. E., Turner, M. A., Yu, X., Kozinetz, C. A., Orozco, A. F., Hutchison, A. T., Savidge, T., et al. (2012) · Journal of Leukocyte Biology · doi:10.1189/jlb.0511264 · Cited by 20
“To explore the role of other TNF family members, we performed the bystander cellkilling assay using blocking antibodies against TNF family members that mediate cell death, such as TNF- , TNF- , or TRAIL.”
BackgroundMethodInfluentialSingh, M., Basu, S., Camell, C. D., Couturier, J. P., Nudelman, R. J., Medina, M. Á., Rodgers, J. R., & Lewis, D. E. (2008) · European Journal of Immunology · doi:10.1002/eji.200737929 · Cited by 17
Animal Models for Autoimmune Hepatitis: Are Current Models Good Enough?
Christen, U., & Hintermann, E. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.898615 · Cited by 19
“In addition, it has been found that although teralizumab showed a similar affinity for mouse, monkey, and human CD28, the induced Ca flux was much lower inmonkey T cells resulting in a decreased activation compared to human T cells (85).”
BackgroundFlow cytometry and receptor occupancy in immune-oncology
Audia, A., Bannish, G., Bunting, R. A., & Riveley, C. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1944098 · Cited by 13
“CD28 Bound aPEG mAb Preclinical PD biomarker [18] PD-1 Bound ahuIgG4 Phase 1 PD biomarker [19] CD20 Free Competing mAb Preclinical PD biomarker [11] CD22 Free Competing mAb Phase 1 PD biomarker [20] CD28 Free Labeled Drug Preclinical PD biomarker [21] CD4 Free Labeled Drug Phase 1 PD biomarker [22] CD40 Free Not deter…”
BackgroundThaventhiran, T., Alhumeed, N., Yeang, H. X., Sethu, S., Downey, J. S., Alghanem, A. F., Olayanju, A., Smith, E., Cross, M. J., Webb, S. D., et al. (2014) · mAbs · doi:10.4161/mabs.29758 · Cited by 11
“general, CD28 ligation in the absence of TCR engagement has no functional effect on T cells; however, CD28SA antibodies can activate T cells without concomitant TCR engagement.(5) Activation of T cells through TCR triggering and CD28 engagement leads to downregulation of cell surface TCR, expression of molecules such…”
BackgroundSternebring, O., Alifrangis, L. H., Christensen, T. F., Ji, H., Hegelund, A. C., & Högerkorp, C. (2015) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21277 · Cited by 11
“, 2008 (15) CD28 Free Labeled Drug Preclinical PD biomarker Zheng et al.”
BackgroundHuman Fcγ receptors compete for TGN1412 binding that determines the antibody's effector function
Dudek, S., Weißmüller, S., Anzaghe, M., Miller, L., Sterr, S., Hoffmann, K., Hengel, H., & Waibler, Z. (2019) · European Journal of Immunology · doi:10.1002/eji.201847924 · Cited by 11
Self-citationIL-2 Inducible Kinase ITK is Critical for HIV-1 Infection of Jurkat T-cells
Hain, A., Krämer, M., Linka, R. M., Nakhaei‐Rad, S., Ahmadian, M. R., Häussinger, D., Borkhardt, A., & Münk, C. (2018) · Scientific Reports · doi:10.1038/s41598-018-21344-7 · Cited by 9
Molecular Insights into γδ T Cell Costimulation by an Anti-JAML Antibody
Verdino, P., Witherden, D. A., Ferguson, M. S., Corper, A. L., Schiefner, A., Havran, W. L., & Wilson, I. A. (2011) · Structure · doi:10.1016/j.str.2010.10.007 · Cited by 11
Czerwiński, M., Kazmi, F., Parkinson, A., & Buckley, D. B. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.060186 · Cited by 8
Iwata, Y., Harada, A., Hara, T., Kubo, C., Inoue, T., Tabo, M., Ploix, C. C., Manigold, T., Hinton, H. J., & Mishima, M. (2016) · The Journal of Toxicological Sciences · doi:10.2131/jts.41.523 · Cited by 7
“Differences were reported in the expression of the target molecule on memory T cells (Eastwood et al., 2010), Ca2+-signal strength (Waibler et al., 2008), inhibitory Siglec-5 molecules (Nguyen et al., 2006), FcγR expression patterns, and binding affinities (Warncke et al., 2012).”
BackgroundA Comparison of Different Immune Activation Strategies to Reverse HIV-1 Latency
Garliss, C. C., Kwaa, A. K., & Blankson, J. N. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa082 · Cited by 4
“Different Activation Strategies for Latency Reversal • ofid • 5 this study we combined PHA with a superagonistic anti-CD28 antibody that provides a co-stimulatory signal and directly activates CD4+ T cells [10].”
BackgroundCD28 Superagonistic Activation of T Cells Induces a Tumor Cell-Like Metabolic Program
Thaventhiran, T., Wong, W., Alghanem, A. F., Alhumeed, N., Aljasir, M. A., Ramsey, S. J., Sethu, S., Yeang, H. X. A., Chadwick, A. E., Cross, M. J., et al. (2019) · Monoclonal Antibodies in Immunodiagnosis and Immunotherapy · doi:10.1089/mab.2018.0042 · Cited by 3
“This is consistent with the activation of the PI3K pathway by engagement of CD28 by the superagonistic mAb.((47)) The acetyl CoA that feeds lipogenesis is primarily derived from citrate.”
Herr, F., Brunel, M., Roders, N., & Dürrbach, A. (2016) · Drugs · doi:10.1007/s40265-016-0656-2 · Cited by 4
“In contrast, CD28 enhances early signals induced by the T-cell receptor through increased phosphorylation and recruitment of some of the signaling components [36, 37]; however, CD28 also induces its own signal [38, 39].”
BackgroundNovel Drugs in Kidney Transplantation
Chandran, S., & Vincenti, F. G. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801734-0.00021-7 · Cited by 1
Schett, G. A. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1090116
Comment on “Regulatory T Cells Protect from Local and Systemic Bone Destruction in Arthritis”
Yuan, F., Lü, W., Li, X., Li, J.-P., Li, C.-W., & Xu, R. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1090115
“This scenario has been observed in a first-in-human trial with a CD28 superagonist Ab, resulting in an acute and dramatic cytokine burst and life-threatening inflammation (3, 4).”
Background8 Visualizing Immune Responses in Fungal Infections: Established and Novel Methods
Hasenberg, M., Krappmann, S., & Gunzer, M. (2013) · Springer eBooks · doi:10.1007/978-3-642-39432-4_8
Self-citationFaculty Opinions recommendation of CD28 costimulation: from mechanism to therapy.
Tuosto, L. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.726363559.793546230
McGeachy, M. J. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.732850338.793546604
Receptomics and Extracellular Interactomics for Biotherapeutic Characterization
Chandan, N. R., Ferrel, A., & Cao, S. (2025) · Wiley eBooks · doi:10.1002/9781394236145.ch17
CD28 : nouvelles données sur un récepteur majeur de la costimulation lymphocytaire T
Morin, S. O. (2017) · theses.fr (ABES) · doi:10.70675/cb01635fz2f63z43e2zad0cz210485c4c5cf
Analyse protéomique et interactomique de l'activation des lymphocytes T humains primaires
Nicolas, P. (2021) · theses.fr (ABES) · doi:10.70675/defcbd86z76d7z43bfz9103zb8a743a479f5
PD-1 blockade enhances T cell activation by reorchestrating CD28 and CTLA4 ligand interactionsPreprint
Eun, G. S., Boyd, J., Au, V., Garcia, A., Čemerski, S., Dovedi, S. J., Pollizzi, K. N., Dustin, M. L., & Varma, R. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.12.718055
Wang, H., Zhao, R., Liu, M., Jiang, T., Sun, D., Chi, L., Huang, Y., Lu, Z., YUN, Y., & Wang, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1812063 · Cited by 1
“This activity is both epitope-and format-dependent, requiring binding to the C ’’ D loop of CD28 and ef fi cient receptor crosslinking by bivalent IgG molecules, which triggers potent intracellular signaling pathways such as nuclear factor kappa-light-chain-enhancer of activated B cells (NF-k B) (6).”
CD28-driven ex vivo generation of stem-like memory CD8 + T cells bypassing CD3/TCR signaling
Ihara, F., Ohashi, Y., Zheng, E. Y. F., Fukao, S., Rodrigo, R., Noamani, B., Boukhaled, G. M., Wang, B., Han, D.-H., Wei, X., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2524626123 · Cited by 1
Sheng, M. K., Firoz, W. A., Loi, K., Vick, L. V., Collins, C. P., Nielsen, R. N., Schmeling, J. L., Gulati, S., Judge, S. J., Canter, R. J., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2026-015074
Metadata
- Authors
- Waibler, Z., Sender, L. Y., Merten, C., Hartig, R., Kliche, S., Gunzer, M., Reichardt, P., Kalinke, U., & Schraven, B.
- Affiliations
- Paul Ehrlich Institut (DE)
- Otto-von-Guericke-Universität Magdeburg (DE)
- Corresponding author
- Kalinke, Ulrich
- Schraven, Burkhart
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-03-05
- Volume
- 3
- Issue
- 3
- Pages
- e1708
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC2246163
- OpenAlex
- W2044984824
- Cited by
- 79
- References
- 46
- Citations by year
- 2026: 4 · 2025: 1 · 2022: 1 · 2021: 4 · 2020: 2 · 2019: 4 · 2018: 4 · 2017: 4 · 2016: 10 · 2015: 3 · 2014: 7 · 2013: 2 · 2012: 8
- FWCI
- 3.48
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Deutsche Forschungsgemeinschaft (SFB 432)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Keywords
- TGN1412, T cell activation, calcium signaling, interferon-gamma, TNF-α, interleukin-2, Src kinase, phosphatidylinositol 3-kinase, regulatory T cells, autoimmune disease therapy, adverse drug reactions, CD4+ T cells
- MeSH terms
- Animals, Antibodies, Monoclonal, Calcium, Flow Cytometry, Humans, Interferon-gamma, Interleukin-2, Lymphocyte Activation, Macaca fascicularis, Macaca mulatta, Quinuclidines, T-Lymphocytes, Tumor Necrosis Factor-alpha, Blotting, Western, Signal Transduction, CD28 Antigens, src-Family Kinases, Cell Proliferation, T-Lymphocytes, Regulatory, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.